First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx

More documents

Recommendations

Info

Classification of TTP Congenital 5% Acquired 95% Secondary 50% Idiopathic (autoimmune) 50% • Drugs • Autoimmune disease • Infections and HIV • Tumours • Pregnancy 4
ADAMTS13 • VWF cleaving protease (ADAMTS13) cleaves ULVWF as soon as these molecules are released by injured or activated endothelial cells • The importance of VWF regulation by ADAMTS13 is demonstrated by the close association between severe deficiency of ADAMTS13 activity and clinical TTP 5
Page 1 and 2: First results of the Phase II TITAN
Page 3: Clinical symptoms at the first thre
Page 7 and 8: Treatment of acute TTP • Survival
Page 9 and 10: Immunosuppressive agents • Cortic
Page 11 and 12: Perspectives • Recombinant ADAMTS
Page 13 and 14: ALX-0081: mode of action in TTP •
Page 15 and 16: ALX-0081 potently neutralises ULVWF
Page 17 and 18: The TITAN trial: study design Inclu
Page 19 and 20: Nanobodies ® - Inspired by nature
Page 21 and 22: Demographic and baseline characteri
Page 23 and 24: PE details • PE treatment - varia
Page 25 and 26: Preliminary observations: RiCo (n =
Page 27 and 28: Preliminary observations: FVIII aci
Page 29 and 30: Preliminary observations: anti-ADAM
Page 31 and 32: Serious adverse events • 2 SAEs r
Page 33: Acknowledgements • Hemophilia and

First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx

Create successful ePaper yourself

Delete template?

Save as template?